Search

Displaying results 3941 - 3950 of 4238 in total
  1. Drug

    AIT-034

    go.drugbank.com/drugs/DB06106
    Experimental

    There is some evidence that AIT-034 could complement Neotrofin as a treatment for Alzheimer's disease and dementia.

  2. Drug

    Oglufanide

    go.drugbank.com/drugs/DB05779
    Investigational

    Oglufanide works as a regulator of the body's immune response, is being given by intranasal administration to patients with chronic hepatitis C viral infection.

  3. Drug

    Meropenem

    go.drugbank.com/drugs/DB00760
    ApprovedInvestigational

    Meropenem is a broad-spectrum carbapenem antibiotic. It is active against Gram-positive and Gram-negative bacteria. Meropenem exerts its action by penetrating bacterial cells readily and interfering with the synthesis of vital cell wall ...

  4. Drug

    Lefradafiban

    go.drugbank.com/drugs/DB04863
    Investigational

    Lefradafiban is an oral platelet glycoprotein IIb/IIIa receptor antagonist being investigated in the treatment of angina.

  5. Drug

    Arotinolol

    go.drugbank.com/drugs/DB09204
    Investigational

    Arotinolol is an alpha- and beta-receptor blocker developed in Japan. It is a thiopropanolamine with a tertiary butyl moiety. It has been studied for its potential to be an antihypertensive therapy. Artinolol is being developed by Sumito...

  6. Drug

    Bebtelovimab

    go.drugbank.com/drugs/DB16755
    ApprovedWithdrawn

    On November 30, 2022, the EUA for bebtelovimab was officially withdrawn due to a lack of efficacy against Omicron subvariants, therefore bebtelovimab is no longer authorized for emergency use in the US

  7. Drug

    Promestriene

    go.drugbank.com/drugs/DB12487
    Investigational

    Promestriene has been studied in phase IV of the clinical trial on improvement of hormonal cytology, local and systemic climacteric complaints, as well as its endometrial security in patients with vaginitis

  8. Drug

    Pipequaline

    go.drugbank.com/drugs/DB13991
    Experimental

    Due to these differences, this drug is classified as a nonbenzodiazepine anxiolytic.

  9. Drug

    G17DT Immunogen

    go.drugbank.com/drugs/DB04914
    Investigational

    It is in phase III trials for advanced pancreatic cancer as a monotherapy and in combination with gemcitabine.

  10. Drug

    DDP733

    go.drugbank.com/drugs/DB05049
    Investigational

    DDP733 is an oral prokinetic drug which Dynogen is developing as a treatment for both Irritable Bowel Syndrome with constipation (IBS-c) and nocturnal gastroesophageal reflux disease (NGERD).